Latest Research And Development News

ClearVue Technologies bolstered its balance sheet with a A$6 million capital raise while landing high-profile projects including Canva’s Sydney HQ and its first European contract in Cyprus. The company also advanced international expansion and achieved key certifications confirming product durability and safety.

Nexus Minerals has completed nearly 22,000m of RC drilling at Wallbrook, delivering strong gold intercepts and setting up an updated resource estimate by September. The company also moved to acquire Northern Star's remaining 10% stake in the Pinnacles JV, consolidating full ownership.

Jindalee Lithium is pushing ahead with its McDermitt Lithium Project in the US, securing shareholder approval for a NASDAQ listing via US Elemental and raising $10.9 million to fund drilling and testwork. The project aims to deliver both lithium and magnesium, aligning with US critical minerals priorities.

Zelira Therapeutics has raised nearly US$33 million into its HOPE® 1 special purpose vehicle, valuing the SPV at about US$66 million post-money. The funds will advance FDA regulatory submissions and Phase 1 clinical trials for its autism-targeting cannabinoid drug.

Island Pharmaceuticals has marked a major step forward in its antiviral program with the start of GMP manufacturing for Galidesivir, expanded USAMRIID collaboration, and FDA orphan drug designation. Regulatory approvals for compassionate use in Uganda’s Ebola outbreak and a new dose optimisation study with Texas Biomed further de-risk the pathway to approval.

EBR Systems advanced its wireless cardiac pacing rollout in Q2 2026, completing 46 implants and signing 17 new purchasing contracts while shifting focus to deeper utilisation within existing accounts.

OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.

BCAL Diagnostics has strengthened its leadership, advanced breast cancer detection tests, and secured key funding and strategic investments to underpin its FY2027 growth plans.

Rhythm Biosciences bolstered its financial position with a $5.2 million option underwriting while accelerating commercial adoption of its ColoSTAT® colorectal cancer test and advancing geneType™ partnerships internationally in Q4 FY26.

Miramar Resources has doubled its gold Exploration Target at the Gidji JV near Kalgoorlie and completed its first drilling program at Chain Pool in over 60 years, while finalising the sale of Randalls Project and securing government grants to fund ongoing exploration.

Avecho Biotechnology has secured a unanimous recommendation to continue its Phase III insomnia trial without increasing sample size, alongside raising $1.9 million through option exercises and bolstering its cash position to $6.6 million.

Cleo Diagnostics has entered the critical Analytical Validation phase for its ovarian cancer blood test, progressing toward an FDA 510(k) submission targeted for the first half of 2027. The company also secured a U.S. reimbursement pathway to support early market entry post-clearance, backed by a cash balance of A$6.2 million.